2017/0328(COD)

European Medicines Agency (EMA): location of the seat

Awaiting Parliament 1st reading / single reading / budget 1st stage

2017/0328(COD) European Medicines Agency (EMA): location of the seat
RoleCommitteeRapporteurShadows
Opinion AFCO BRESSO Mercedes (S&D)
Opinion AGRI
Opinion BUDG
Opinion CONT FLANAGAN Luke Ming (GUE/NGL)
Lead ENVI LA VIA Giovanni (EPP) BORZAN Biljana (S&D), KRUPA Urszula (ECR), RIES Frédérique (ALDE), KONEČNÁ Kateřina (GUE/NGL), AUKEN Margrete (Verts/ALE), PEDICINI Piernicola (EFD), MÉLIN Joëlle (ENF)
Opinion ITRE
Lead committee dossier: ENVI/8/11697
Legal Basis Rules of Procedure EP 59-p4
Subjects
Links

Activites

  • 2018/03/15 Matter referred back to the committee responsible
  • 2018/03/15 Results of vote in Parliament
    • Results of vote in Parliament
    • T8-0086/2018 summary
  • 2018/03/12 Vote in committee, 1st reading/single reading
    • A8-0063/2018 summary
    • AFCO BRESSO Mercedes S&D
    • AGRI
    • BUDG
    • CONT FLANAGAN Luke Ming GUE/NGL
    • ENVI ENVI/8/11697 LA VIA Giovanni EPP
    • ITRE
  • 2017/12/11 Committee referral announced in Parliament, 1st reading/single reading
  • 2017/11/29 Legislative proposal published
    • COM(2017)0735 summary
    • DG {u'url': u'http://ec.europa.eu/info/departments/health-and-food-safety_en', u'title': u'Health and Food Safety'}, ANDRIUKAITIS Vytenis Povilas

Documents

Votes

A8-0063/2018 - Giovanni La Via - Am 16

2018/10/25
Position Total ALDE ECR EFDD ENF GUE/NGL NI PPE S&D Verts/ALE correctional
For 425 54 32 8 6 27 4 152 103 39 0
Against 71 0 6 25 7 3 3 5 22 0 0
Abstain 56 1 16 1 16 1 3 0 17 1 0
AmendmentsDossier
2 2017/0328(COD) European Medicines Agency (EMA): location of the seat
2018/02/08 AFCO 2 amendments...
source: PE-616.913

History

(these mark the time of scraping, not the official date of the change)

2018-09-12
activities/0/commission/0 added
DG
Commissioner
ANDRIUKAITIS Vytenis Povilas
activities/0/docs/0/text added
  • PURPOSE: to relocate the seat of the European Medicines Agency (EMA) following the notification by the United Kingdom to the European Council of its intention to leave the Union.

    PROPOSED ACT: Regulation of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

    BACKGROUND: the European Medicines Agency has been established by Regulation (EEC) No 2309/93, which has been replaced by Regulation (EC) No 726/2004.

    In accordance with the Decision of 29 October 1993 taken by common agreement between the representatives of the governments of the Member States, meeting at Head of State and Government level, on the location of the seats of certain bodies and departments of the European Communities and of Europol, the European Medicines Agency has its seat in London, United Kingdom.

    Following the notification by the United Kingdom of its intention to leave the Union, the 27 remaining Member States, in the margins of the General Affairs Council (Article 50), selected Amsterdam, the Netherlands, as the new seat for the European Medicines Agency.

    CONTENT: the Commission proposes to amend Regulation (EC) No 726/2004 in order to confirm the new seat of the European Medicines Agency in Amsterdam, the Netherlands.

    The Agency should occupy its new seat from the date on which the Treaties cease to apply to the United Kingdom or from 30 March 2019, whichever is the earlier.

    It is proposed that the Regulation shall enter into force as a matter of urgency in order to give the Agency sufficient time to relocate.

    BUDGETARY IMPLICATION: the relocation of the Agency will have budgetary implications, in particular in view of the costs related to the early termination of its current rental contract in London as a consequence of the withdrawal, the costs related to the move itself and the costs related to the installation in the new premises in Amsterdam.

    As set out in the negotiation directives of the Council of 22 May 2017, the United Kingdom should fully cover the specific costs related to the withdrawal process, such as the relocation of the agencies based in the United Kingdom.

    Some of the relocation costs (e.g. costs related to the move itself) may have to be pre-financed by the EU budget prior to the final financial settlement. If necessary, the Commission will submit the relevant proposals to the European Parliament and the Council in the framework of the annual budgetary procedure for 2019 and, if necessary, for 2018.

    In addition, the costs related to the installation in the new premises will also be presented in the context of the building procedure set out in Article 203 of the Financial Regulation, which requires prior approval from the European Parliament and the Council before contracts related to building projects are concluded. This procedure is expected to be launched as soon as possible (at the latest in early 2018).

activities/1 added
date
2017-12-11
body
EP
type
Committee referral announced in Parliament, 1st reading/single reading
committees
activities/2 added
date
2018-03-12
body
EP
type
Vote in committee, 1st reading/single reading
committees
docs
  • url
    http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0063&language=EN
    text
    • The Committee on the Environment, Public Health and Food Safety adopted the report Giovanni LA VIA (EPP, IT) on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency.

      As a reminder, the Commission proposal aims at amending Regulation (EC) No 726/2004 in order to confirm the seat of the European Medicines Agency in Amsterdam, the Netherlands.

      The committee recommended that the European Parliament’s position adopted at first reading under the ordinary legislative procedure should amend the Commission proposal as follows.

      According to Members, having a precise timeline in the legislation for the signature of the headquarters agreement is required to prevent delays in the HQ agreement's negotiations and thus to support the preparatory activities for the relocation by 30 March 2019. The headquarters agreement shall include the most appropriate terms and conditions for the successful relocation of the European Medicines Agency and its staff members to Amsterdam.

      In order to ensure the Agency’s full business continuity, the temporary location in Amsterdam should be provided as of 1 January 2019 and the permanent headquarters of the Agency should be completed by 15 November 2019. The Commission and the Dutch authorities shall take all the necessary measures to ensure that the Agency can move to its temporary location no later than 1 January 2019 and that it can move to its permanent location no later than 16 November 2019.

      A headquarters agreement allowing the Agency to take up its duties at the premises approved by the European Parliament and the Council shall be concluded within three months from the date this Regulation enters into force.

      In a statement annexed to this resolution, Parliament regretted that its role of co-legislator has not been duly taken into account since it was not involved in the procedure leading to the selection of the new seat of the European Medicines Agency (EMA). It recalled its prerogatives as co-legislator and insisted on the full respect of the ordinary legislative procedure in relation to the location of bodies and agencies, while insisting that the procedure followed for the selection of a new location for the agencies will be reformed and not used anymore in this form in the future.

    type
    Committee report tabled for plenary, 1st reading/single reading
    title
    A8-0063/2018
activities/3 added
date
2018-03-15
body
unknown
type
Matter referred back to the committee responsible
activities/4 added
date
2018-03-15
docs
body
EP
type
Results of vote in Parliament
committees/0/date added 2018-02-26
committees/0/rapporteur added
  • group
    S&D
    name
    BRESSO Mercedes
committees/3/date added 2018-01-11
committees/3/rapporteur added
  • group
    GUE/NGL
    name
    FLANAGAN Luke Ming
committees/4/date added 2018-01-10
committees/4/rapporteur added
  • group
    EPP
    name
    LA VIA Giovanni
committees/4/shadows added
  • group
    S&D
    name
    BORZAN Biljana
  • group
    ECR
    name
    KRUPA Urszula
  • group
    ALDE
    name
    RIES Frédérique
  • group
    GUE/NGL
    name
    KONEČNÁ Kateřina
  • group
    Verts/ALE
    name
    AUKEN Margrete
  • group
    EFD
    name
    PEDICINI Piernicola
  • group
    ENF
    name
    MÉLIN Joëlle
other/0 added
body
EC
dg
commissioner
ANDRIUKAITIS Vytenis Povilas
procedure/Modified legal basis added Rules of Procedure EP 150
procedure/dossier_of_the_committee added ENVI/8/11697
procedure/legal_basis added
  • Rules of Procedure EP 59-p4
procedure/stage_reached changed
Old
Preparatory phase in Parliament
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
2017-12-11
2017-12-10
2017-12-05

code AGPLv3.0+, data ODBLv1.0, site-content CC-By-Sa-3.0
© European Union, 2011 – Source: European Parliament